Expand ENTA Menu
ENTA MENU

ENTA Latest Press Releases

-- June 23, 2026 --

Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Business Wire 5:10 AM

-- June 18, 2026 --

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) Business Wire 7:00 AM

-- May 28, 2026 --

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference Business Wire 7:00 AM

-- May 11, 2026 --

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 Business Wire 4:01 PM

-- May 4, 2026 --

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 Business Wire 7:00 AM

-- April 13, 2026 --

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria Business Wire 7:00 AM

-- April 7, 2026 --

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 Business Wire 7:00 AM

-- March 30, 2026 --

Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) Business Wire 7:00 AM

-- March 3, 2026 --

Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference Business Wire 7:00 AM
Market Data Delayed 15 Minutes